








Michael A. Narachi - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Michael A. Narachi
Dir., President and Chief Executive Officer at Orexigen Therapeutics, Inc.


View Full Profile
Are you Michael A. Narachi? Claim your profile


 


Sign up for Equilar Atlas and view Michael A. Narachi's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Michael A. Narachi's  network and community.
												FOLLOW changes in Michael A. Narachi's employment and money-in-motion.
												CONNECT with Michael A. Narachi through your network of contacts.
												








Michael A. Narachi's Executive Work History


Current


Dir., President and Chief Executive Officer, 
Orexigen Therapeutics, Inc.


Board Member, 
Ultragenyx Pharmaceutical Inc.


Past
To view Michael A. Narachi's complete executive work history, sign up now
Education


														 B.S., 
															University of California - Davis


														 M.B.A., 
															University of California - Los Angeles


Age
57

 
 


Michael A. Narachi's Biography



Michael A. Narachi has served as our President and Chief Executive Officer and a member of our board of directors since March 2009. Previously, Mr. Narachi served as chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2003. M ...
(Read More)

			Michael A. Narachi has served as our President and Chief Executive Officer and a member of our board of directors since March 2009. Previously, Mr. Narachi served as chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN�; Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He currently serves as a member of the board of directors of Ultragenyx Pharmaceutical Inc., a publicly traded biopharmaceutical company, and previously served as the chairman of the board of directors of Celladon Corporation, a publicly traded biotechnology company, from 2013 until 2016, and as a member of the board of directors of AMAG Pharmaceuticals, Inc. from 2006 until 2014. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.
Key Attributes, Experience and Skills and the Benefit to the Board of Directors include:
Mr. Narachi brings to our board of directors valuable business, leadership and management experience, and knowledge of our company and the biotechnology industry. Mr. Narachi's services as our President and Chief Executive Officer provide a critical link between management and the board of directors and ensures that the board takes into consideration management's perspectives on the business. This critical link also helps the board to perform its oversight function.
		
Source: Orexigen Therapeutics, Inc. on 05/30/2017
		
	

 






Sign up for Equilar Atlas and view Michael A. Narachi's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Michael A. Narachi. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Michael A. Narachi's  network and community.
												FOLLOW changes in Michael A. Narachi's employment and money-in-motion.
												CONNECT with Michael A. Narachi through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Michael A. Narachi


















Michael A. Narachi's Connections (220)





Sign up now to view Michael A. Narachi's 220 connections »









Eckard Weber
Chairman of the Board, Ocera Therapeutics, Inc.









Paul J. Hastings
Chairman of the Board, Chief Executive Officer and President, OncoMed Pharmaceuticals, Inc.









Louis C. Bock
Board Member, Orexigen Therapeutics, Inc.









Steven J. Mento
Dir., President, Chief Executive Officer and Acting Principal Financial Officer, Conatus Pharmaceuticals Inc.









Brian H. Dovey
Board Member, Orexigen Therapeutics, Inc.









Kleanthis G. Xanthopoulos
Board Member, Apricus Biosciences, Inc.









Stuart A. Arbuckle
Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals Incorporated









Luigi Lenaz
Lead Director, Spectrum Pharmaceuticals, Inc.









Clay B. Siegall
President, Chief Executive Officer and Chairman of the Board, Seattle Genetics, Inc.









David M. Stout
Board Member, Jabil, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









David J. O'Connor
President and CEO, The Madison Square Garden Company









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993













 






Michael Narachi, Chairman, Celladon


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Michael Narachi



Chairman
at
Celladon


Location: San Diego, CA





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Michael Narachi



Chairman
at
Celladon


Location: San Diego, CA




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Michael currently serves as President and Chief Executive Officer of Orexigen Therapeutics, Inc. Michael has 29 years of biotechnology and pharmaceutical experience across a broad range of functions including clinical development, commercialization, strategic business development and planning. Prior to joining Orexigen, Michael served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company and Executive Chairman of the Board of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen’s Anemia Business. Throughout his 20 years at Amgen, Michael held various positions including: Product Development Team Leader for NEUPOGEN; Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also Chairman of AMAG Pharmaceuticals, Inc. and a member of the Board of Directors at the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).



3

Companies in Career





N/A

Related Markets





4

Colleagues





N/A

Related Investments








Alias
N/A



Industry
R&D in Biotech, Environmental and various industries (no marketing product yet)




Tags
N/A




Topics of Influence












Web Site







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Michael NarachiCareer (3)






Oct-2013




Celladon



Chairman







2009




Orexigen Therapeutics



President and Chief Executive Officer












Ren Pharmaceuticals, Inc



Chairman, Chief Executive Officer and President








Competencies










 Edit
View all 



Michael NarachiEducation (3)










UCLA Anderson School of Management









1984



University of California









1984



University of California












 Edit



Michael NarachiAchievements and Recognitions





Add Milestone


No milestones has been recorded for Michael Narachi






 Edit



Michael NarachiLinks





Add Link


No links has been recorded for Michael Narachi









Michael NarachiInvestments/Acquisitions





No investments has been recorded for Michael Narachi









Michael NarachiInvestments Representing Others





No investment reps has been recorded for Michael Narachi








Michael NarachiRelated People








Colleagues at Celladon







Patrick Yang

Board of Director
Mar-2014









Peter Honig

Board of Director
Mar-2014









Graham Cooper

Board of Director
Sep-2013









Gregg Alton

Board of Director
Sep-2013












View all 



Michael NarachiRecommended Market Profiles (8)








Telemedicine

10,000 or More employees
19 companies








Social Media Marketing (ChiefMartec.com)

5,000 - 10,000 employees
111 companies








Big Data Universe List of Lists

10,000 or More employees
533 companies








Aggregated Marketing Technology

10,000 or More employees
2650 companies








Shared Economy Landscape (Jeremiah Owyang)

10,000 or More employees
267 companies








Inside Sales Landscape

10,000 or More employees
650 companies




















Michael Narachi, Orexigen Therapeutics Inc: Profile & Biography - Bloomberg


































































  




























Feedback





Michael "Mike" Narachi

President/CEO,
Orexigen Therapeutics Inc






Career History




President/CEO
Orexigen Therapeutics Inc, 6/2016-PRESENT


President/CEO/Interim CFO
Orexigen Therapeutics Inc, 12/2015-6/2016


President/CEO
Orexigen Therapeutics Inc, 3/2009-12/2015


Chairman/President/CEO
Ren Pharmaceuticals Inc, 11/2006-3/2009


Chairman
Naryx Pharma Inc, 8/2002-1/2008


VP & COO:Anemia Business
Amgen Inc, UNKNOWN-2004


Chairman
Sinuspharma Inc, 8/2004-UNKNOWN


Chairman
Sinuspharma Inc, 8/2004-UNKNOWN


Chairman
Sinuspharma Inc, 8/2004-UNKNOWN


VP:Dev/Representative Dir
Amgen Japan, FORMER



Amgen Inc, FORMER


Head:Corporate Strategic
Amgen Inc, FORMER


VP:Licensing & Business Dev
Amgen Inc, FORMER


Show More









Website:
www.orexigen.com






Corporate Information
Address:

3344 NorthTorrey Pines Court
Suite 200
La Jolla, CA 92037
United States


Phone:
1-858-875-8600


Fax:
1-858-875-8650


Web url:
www.orexigen.com











From The Web












Personal Information



Education



University of California
Master's Degree, 1984


University of California
Bachelor's Degree, Biology


Anderson University Graduate School of Management
MBA


Show More








Memberships



Board Memberships




Biotechnology Innovation Organization


Board Member, 1/2016-PRESENT




Ultragenyx Pharmaceutical Inc


Board Member, 2/2015-PRESENT




Pharmaceutical Research & Manufacturers of America


Board Member, 4/2013-PRESENT




Orexigen Therapeutics Inc


Board Member, 3/2009-PRESENT




Celladon Corp


Chairman, 10/2013-3/2016




Biotech Industry Org


Board Member, UNKNOWN-1/2016




Amag Pharmaceuticals Inc


Chairman, UNKNOWN-4/2014




Ren Pharmaceuticals Inc


Miscellaneous, 11/2006-3/2009




Naryx Pharma Inc


Chairman, 8/2002-1/2008




Advanced Magnetics Inc


Board Member, 11/2006-7/2007




Amag Pharmaceuticals Inc


Board Member, 7/2007-UNKNOWN




Sinuspharma Inc


Chairman, 8/2004-UNKNOWN



Show More








Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data







































Michael Narachi






















 




Search








 


Search

 


  
 



Home 

NewsNewsPharmaceutical NewsBiotechnology NewsGenerics NewsBiosimilars newsMergers & AcquisitionsRegulationWorld NewsTop News Stories

People with chronic kidney disease should be offered statins, says NICEPharmaceuticalWHO prequalification for generic SovaldiGenerics 

In DepthIn DepthAnalysisSpecial ReportInterviewIn conversation with ....Expert ViewFrom our correspondentIn the BoardroomTop In Depth Stories

After 15 years of failure, what can pharma offer Alzheimer's patients?PharmaceuticalPatient Centricity: making clinical trials more effective by keeping focus on the patientPharmaceutical 

Conference RoundupConference RoundupAAIC 2017EULAR 2017EASL 2017ASCO 2017AACR Annual Meeting 2017ECTRIMS 2016Top Conference Roundup Stories

People with chronic kidney disease should be offered statins, says NICEPharmaceuticalWHO prequalification for generic SovaldiGenerics 

Focus OnFocus OnBrexitFDAPricingEMARussian marketTrump administrationTop Focus On Stories

Inquiry asks how to stimulate UK life sciences innovationPharmaceuticalBrexit and longer-term sector trends could boost UK pharma M&A/investmentBiotechnology 

Events 

Companies 

Reports 











 
          Michael Narachi        


Orexigen Therapeutics President and Chief Executive Officer 
President and Chief Executive Officer, Orexigen Therapeutics Michael Narachi has served as President and Chief Executive Officer and a member of our board of directors since March 2009. Previously, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. In 2004, Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2003.
Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN® Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He currently serves on the board of directors of Amag Pharmaceuticals, Inc., a publicly traded pharmaceutical company.
Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles. Mr. Narachi also currently serves as a member of the Board of Directors of PhRMA, the Pharmaceutical Research and Manufacturers of America; BIO, the Biotechnology Industry Organization; and AMAG Pharmaceuticals, Inc., a publicly traded pharmaceutical company.


















 

Related Pharma Letter News

Orexigen files for Canadian approval of weight loss drugThe obesity epidemic: what is pharma doing?Orexigen targets growing obesity problem in Spain 
More Pharma Letter News 

Related news from the web

Monday Sector Leaders: Biotechnology, Music & Electronics Stores 
More Related News 
 

Orexigen TherapeuticsUS biopharma company Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company focused on the treatment of obesity.





Editor's Picks 

Most read 



Top 5 Stories1 of 5In Alzheimer's, the 'juggernaut is changing course,' says TauRx chief execEpigenetic biomarkers set to make “a huge difference in human health,” says Cambridge Epigenetix’s Tiffany MorrisEMA/CHMP recommends eight new drugs for approval, including five orphansBrexit and longer-term sector trends could boost UK pharma M&A/investmentSuccess of Chinese pilot a step forward in the ‘globalization of drug regulation’Top 5 Stories1 of 5Pfizer’s biosimilar shows similarity to AvastinNICE recommends treatment with Daxas for COPDBiogen lures Novartis executive to its teamChiesi cleared to market COPD drug in EuropeLonza and Sanofi to build new multidisciplinary biomanufacturing facility in Switzerland

 Company SpotlightZymeworksZymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multi-functional bio-therapeutics, initially focused on the treatment of cancer. 




Tweets












Sign up for our daily newsletter
Our latest news direct to your inbox






Newsletter













 


 



Back to top






Ultragenyx Appoints Michael Narachi to Board of Directors (NASDAQ:RARE)
























 



Facebook
Google
LinkedIn
Twitter
Email
RSS





Feb 24, 2015



 Previous Release | Next Release 


PDF

Add to Briefcase
File is in Briefcase



Ultragenyx Appoints Michael Narachi to Board of Directors

NOVATO, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Michael Narachi to the company's Board of Directors effective February 20, 2015. Mr. Narachi, President and Chief Executive Officer and a director of Orexigen Therapeutics Inc., will serve as an independent director to Ultragenyx.

	"On behalf of the Board of Directors and Executive Team at Ultragenyx, I am pleased to welcome Mike to the Board. With his proven track record leading young biotech companies, Mike's broad expertise and diverse experience will be of tremendous value to Ultragenyx as it enters the next phase of its development," said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer of Ultragenyx.

	"I am excited to join Ultragenyx at a critical time of the company's growth and to be a part of the continued progress of advancing drug development to addressing severe and potentially life-threatening diseases," said Mr. Narachi. "I look forward to working closely with the Board and the Ultragenyx team to bring therapies to patients affected by these rare and ultra-rare diseases."

	Mr. Narachi currently serves as President and Chief Executive Officer and a director of Orexigen Therapeutics Inc., a position he has held since March 2009. Previously, Mr. Narachi served as Chairman, Chief Executive Officer and President of Ren Pharmaceuticals, Inc., a private biotechnology company, from November 2006 to March 2009. From August 2002 to January 2008, Mr. Narachi served as chairman of the board of directors of Naryx Pharma, Inc., a private pharmaceutical company. Mr. Narachi joined Amgen in 1984 and held various senior positions throughout the organization over a 20 year career including: Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development.  He served as General Manager of Amgen's Anemia Business from 1999 to 
2003 until his retirement in 2004 as an officer and Vice President of Amgen, Inc. He currently serves as the chairman of the board of directors of Celladon Corporation, a publicly traded biotechnology company. Mr. Narachi received a B.S. in Biology and an M.A. degree in Biology and Genetics from the University of California at Davis. He received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.About Ultragenyx

	Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

	The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

	For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.CONTACT: Ultragenyx Pharmaceutical Inc.

         844-758-7273

         For Media, Bee Nguyen

         For Investors, Robert Anstey









 

	
        Compensation Information for Michael A. Narachi , President, Chief Executive Officer and Member of the Board of Directors of OREXIGEN THERAPEUTICS INC | Salary.com
    


























Enterprise
Small Business
Personal




Contact Us
Log In


































Salaries
Jobs
Education
Advice
























 





Michael A. Narachi 
Executive Compensation
As President, Chief Executive Officer and Member of the Board of Directors at OREXIGEN THERAPEUTICS INC, Michael A. Narachi  made $5,213,561 in total compensation.  Of this total $679,639 was received as a salary, $458,756 was received as a bonus, $3,202,700 was received in stock options, $864,000 was awarded as stock and $8,466 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year. 


ENTER AN EXECUTIVE OR COMPANY NAME
New Search


Go



The chart on this page features a breakdown of the total annual pay for Michael A. Narachi ,  President, Chief Executive Officer and Member of the Board of Directors at OREXIGEN THERAPEUTICS INC as reported in their proxy statements. 
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. OREXIGEN THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. OREXIGEN THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.
Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.



Other Executives at this Company


Thomas  Lynch 
Thomas  Cannell D.V.M








Michael A. Narachi 


Base Pay$679,639
Bonus + Incentive Comp$458,756
Total Cash Compensation$1,138,395


Stock Award Value$864,000
Option Award Value$3,202,700
Total Equity$4,066,700



Total Other$8,466



Total Compensation$5,213,561




Browse Executives by First Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z


Browse Companies by Company Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#



This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement. 
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.







    





 

 






     

privacy policy
terms of use
about us
contact us

©  Salary.com. All rights reserved.


US Salaries
Canadian Salaries
Purchase a Salary Report
Salaries by Category
Salaries by Income
Salaries by Industry
Popular Salaries
Negotiation Tips
Benefits Calculator
Search Job Openings
Job Openings by State
Job Openings by Category
Education by Career
Education by Level
Education by Major
Cost of Living Calculator
























 



OREX Michael A. Narachi Insider Trades for Orexigen Therapeutics Inc.


































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Orexigen Therapeutics Inc.

                  NASDAQ: OREX
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Orexigen Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 26, 2017, 7:02 p.m.


OREX

/quotes/zigman/74179353/composite


$
2.40




Change

-0.14
-5.51%

Volume
Volume 650
Quotes are delayed by 20 min








/quotes/zigman/74179353/composite
Today's close

$
			2.40
		


$
				2.54
			
Change

+0.14
+5.83%





Day low
Day high
$2.42
$2.60










52 week low
52 week high

            $1.65
        

            $5.70
        


















Insider Activity


Individual




Michael A. Narachi



Mr. Michael A. Narachi is on the Board of Directors at Ultragenyx Pharmaceutical, Inc., Pharmaceutical Research & Manufacturers of America, Orexigen Therapeutics, Inc. and Biotechnology Industry Organization. Mr. Narachi was previously employed as Chairman by Celladon Corp., Chairman, President & Chief Executive Officer by Ren Pharmaceuticals, Inc., Executive Chairman by Naryx Pharma, Inc., and Executive Vice President by Amgen, Inc. He also served on the board at AMAG Pharmaceuticals, Inc. He received his undergraduate degree from the University of California, Davis, a graduate degree from the University of California, Davis and an MBA from UCLA Anderson School of Management.



Transactions


Date
Shares
Transaction
Value





05/31/2017
626


 
Award at $1.55 per share.


970


11/30/2016
802


 
Award at $1.67 per share.


1,339


05/31/2016
8,777


 
Award at $0.34 per share.


2,984


11/30/2015
1,761


 
Award at $2.03 per share.


3,574


05/29/2015
721


 
Award at $4.17 per share.


3,006


09/15/2014
50,000


 
Acquisition at $4.78 per share.


239,000


11/29/2013
3,980


 
Award at $5.34 per share.


21,253





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Michael A. Narachi 
President, Chief Executive Officer & Director




Dr. Thomas R. Cannell 
Chief Operating Officer & Executive Vice President




Mr. Jason  Keyes 
Chief Financial Officer & Senior Vice President




Ms. Beth  Eastland 
Vice President-Sales




Mr. Stephen A. Moglia 
Principal Accounting Officer




Mr. Thomas P. Lynch 
Secretary, Executive VP & General Counsel




Dr. Peter D. Flynn 
SVP, Head-Development, Regulatory Affairs & Safety




Mr. Patrick J. Mahaffy 
Chairman




Ms. Deborah A. Jorn 
Independent Director




Ms. Lota S. Zoth 
Independent Director




Mr. Louis C. Bock 
Independent Director




Mr. Brian H. Dovey 
Independent Director




Mr. David J. Endicott 
Independent Director




Dr. Peter K. Honig 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:23 PM EDT
July 26, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:56pThis social network ranks as the worst for young people’s mental health (it’s not Facebook)
9:55pMove over, breathalyzers; ‘textalyzers’ could be used on drivers’ phones 
9:55pThis is the worst mistake people make at work
9:54pCities to move to if you want to work in tech — NOT including San Francisco
9:54pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
9:50pWatch out for these surprise charges at the ER
9:49pThe open road or the open skies? Millennials choose the former...
9:48pHow an online wedding registry in my name appeared out of thin air
9:47pDon’t have a college degree? These are the industries with the best-paid jobs
9:46pThe highest paid athletes in the world, in one chart
9:46pHow to teach your kids to be better with money than you are
9:40pBack-to-school shopping goes mainstream with deals on eyewear, fitness apparel and kitchen appliances
9:39pSamsung posts record profits on back of strong Galaxy S8 sales
9:39pThe dark side of cruises
9:37pFor transgender Americans, workplace discrimination isn’t limited to the military
7:46pScaramucci on Washington back stabbers: ‘I’m more of a front-stabbing person’
7:43pFacebook keeps warning about growth, but growth doesn’t stop
6:56pFacebook heads toward $500 billion market cap after earnings
6:46pFoxconn pledges to build $10 billion state-of-the-art electronics plant in Wisconsin
6:14pGraham says Trump is showing weakness in unilateral public spat with Sessions
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,711.01

+97.58
+0.45%





nasdaq

/quotes/zigman/12633936/realtime
6,422.75

+10.57
+0.16%





s&p 500

/quotes/zigman/3870025/realtime
2,477.83

+0.70
+0.03%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































    Michael Narachi | Orexigen Therapeutics , Inc. | ZoomInfo.com